We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Thrombogenics Awarded €1.1 Million IWT Research Grant
News

Thrombogenics Awarded €1.1 Million IWT Research Grant

Thrombogenics Awarded €1.1 Million IWT Research Grant
News

Thrombogenics Awarded €1.1 Million IWT Research Grant

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Thrombogenics Awarded €1.1 Million IWT Research Grant"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ThromboGenics NV has announced that it has been awarded a €1.1 million research grant from the Flemish agency for Innovation by Science and Technology (IWT).

The grant will be used by Thrombogenics to fund the on-going research to further elucidate the pharmacological effects ocriplasmin is exerting in the back of the eye following intravitreal (IVT) injection.

Dr Patrik De Haes, CEO of ThromboGenics comments: “The award of this grant from IWT supports our commitment to gain further insight into JETREA®s action in the vitreo-retinal interface. In conjunction with a growing body of real world and clinical trial data, we hope that the continual efforts at the preclinical research level will contribute to an improved awareness and acceptance of JETREA® by physicians as a first in class pharmaceutical treatment for symptomatic VMA.”

Advertisement